U.S. General Anesthesia Drugs Market Worth $2 Billion by 2020

Jul 24, 2015, 05:30 ET from MarketsandMarkets

DALLAS, July 24, 2015 /PRNewswire/ --

According to a new market research report "U.S. General Anesthesia Drugs Market by Molecule (Propofol, Benzodiazepines, ketamine(s(+) ketamine HCl), Methohexital Sodium), route of administration (Intravenous, Inhalational), Supply Chain (GPOs, Distributors), Competitive - Analysis Forecast to 2020", published by MarketsandMarkets, The U.S. General Anesthesia Drugs Market is expected to reach around $2 Billion by 2020 at a CAGR of 3.8% from 2015 to 2020.

Browse 42 market data Tables and 28 Figures spread through 114 Pages and in-depth TOC on "U.S. General Anesthesia Drugs Market"

http://www.marketsandmarkets.com/Market-Reports/anesthesia-drugs-ketamine-market-713.html

Early buyers will receive 10% customization on this report. 

The U.S. general anesthesia drugs market is poised to reach ~ USD 2.0 billion by 2020 from USD 1.6 billion in 2015, at a CAGR of 3.8% from 2015 to 2020.

Factors such as rapid rise in aging population, rising prevalence of cardiovascular and respiratory system-related diseases, and rising number of emergency surgeries are driving the growth of the U.S. general anesthesia drugs market. However, side effects associated with ketamine usage (such as elevation in blood pressure and heart rate, amnesia, respiratory depression, and hallucinations), regulatory issues, and lower compliance rates in comparison with other anesthetic drugs are likely to restrain the growth of this market.

Ask for PDF Brochure @ http://www.marketsandmarkets.com/pdfdownload.asp?id=713

The market is segmented on the basis of molecule and route of administration. On the basis of molecules, the market is divided into Propofol, Benzodiazepine, Ketamine (S-(+)-Ketamine HCL), and Methohexital Sodium. Propofol is expected to be fastest-growing segment, owing to its greater preference and rapid onset of action.

On the basis of route of administration, the U.S. general anesthesia drugs market is bifurcated into intravenous and inhalational. The intravenous segment is expected to account for the largest share of the U.S. general anesthesia drugs market in 2015. Greater patient compliance and less number of side effects as compared to inhalational anesthetics are driving the growth of this market.

Major players operating in the U.S. General Anesthesia Drugs Market are AstraZeneca plc (U.K.), Baxter International Inc. (U.S.), Hikma Pharmaceuticals PLC (U.K.), Mylan N.V. (U.S.), Eisai Co., Ltd. (Japan), Fresenius Se & Co. KGaA (Germany), Hospira, Inc. (U.S.), and Par Pharmaceutical Companies, Inc. (U.S.).

Browse Related Reports: 

Operating Room Management Market by Product (Data Management, Anesthesia, Surgical, Performance), Application (Perioperative, Preoperative, OR Scheduling), Component (Software, Services), Delivery Mode (Web-Based, On-Premise) Global Forecast to 2019

Published Date: October 2014

http://www.marketsandmarkets.com/Market-Reports/operating-room-management-market-175407912.htm

Global Anesthesia and Respiratory Devices Market (2010-2015)

Published Date: February 2011

http://www.marketsandmarkets.com/Market-Reports/respiratory-devices-349.html

About MarketsandMarkets 

 MarketsandMarkets is world's No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.

M&M's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Contact:
Mr. Rohan
North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas, TX 75252
Tel: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/pharmaceuticals
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets


SOURCE MarketsandMarkets